埃罗妥珠单抗用于治疗多发性骨髓瘤。
Elotuzumab for the treatment of multiple myeloma.
作者信息
Moreau Philippe, Touzeau Cyrille
机构信息
Hematology Department, University Hospital Hotel-Dieu, 44093, Nantes, France.
出版信息
Future Oncol. 2014 May;10(6):949-56. doi: 10.2217/fon.14.56.
New agents are awaited for the treatment of multiple myeloma and research is ongoing for the development of monoclonal antibodies (MoAbs) targeting the tumor cells. One of the most promising MoAb is elotuzumab, the only humanized IgG1 MoAb specifically targeting CS1 (SLAMF7), a cell surface glycoprotein that is highly expressed in plasma cells. Preclinical and clinical data on elotuzumab will be presented in this article.
人们期待有新的药物用于治疗多发性骨髓瘤，针对肿瘤细胞的单克隆抗体（MoAb）的研发工作也在持续进行。最有前景的单克隆抗体之一是埃罗妥珠单抗，它是唯一一种特异性靶向CS1（信号淋巴细胞激活分子家族成员7）的人源化IgG1单克隆抗体，CS1是一种在浆细胞中高度表达的细胞表面糖蛋白。本文将介绍关于埃罗妥珠单抗的临床前和临床数据。
Zotero 插件